MX362212B - Metodo para la deteccion de mutaciones de braf y pi3k. - Google Patents

Metodo para la deteccion de mutaciones de braf y pi3k.

Info

Publication number
MX362212B
MX362212B MX2015003386A MX2015003386A MX362212B MX 362212 B MX362212 B MX 362212B MX 2015003386 A MX2015003386 A MX 2015003386A MX 2015003386 A MX2015003386 A MX 2015003386A MX 362212 B MX362212 B MX 362212B
Authority
MX
Mexico
Prior art keywords
mutations
primers
present
braf
detection
Prior art date
Application number
MX2015003386A
Other languages
English (en)
Other versions
MX2015003386A (es
Inventor
Moscoso Del Prado Juan
Luisa Villahermosa María
Original Assignee
Genomica Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomica Sau filed Critical Genomica Sau
Publication of MX2015003386A publication Critical patent/MX2015003386A/es
Publication of MX362212B publication Critical patent/MX362212B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se refiere a un método para detección de mutaciones de BRAF V600E y V600K, donde el método comprende las etapas de; someter una muestra a ensayar que comprende ácidos nucleicos a amplificación con una mezcla de amplificación que comprende dos cebadores ARMS, donde los dos cebadores ARMS son de ID SEC NO: 3 e ID SEC NO; 4, la mezcla de amplificación comprende además un cebador de amplificación que comprende o consiste en ID SEC NO: 5; y la detección de cualquier producto de amplificación que se obtenga, mediante hibridación de dicho producto con dos o más sondas, donde cada sonda hibrida específicamente con la región en el producto de amplificación correspondiente a la secuencia marcadora en 5´del cebador ARMS correspondiente.
MX2015003386A 2012-09-21 2013-09-20 Metodo para la deteccion de mutaciones de braf y pi3k. MX362212B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12382370.0A EP2711432A1 (en) 2012-09-21 2012-09-21 Method for detection of BRAF and PI3K mutations
PCT/EP2013/069634 WO2014044828A1 (en) 2012-09-21 2013-09-20 Method for detection of braf and pi 3k mutations

Publications (2)

Publication Number Publication Date
MX2015003386A MX2015003386A (es) 2015-06-05
MX362212B true MX362212B (es) 2019-01-09

Family

ID=46940438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003386A MX362212B (es) 2012-09-21 2013-09-20 Metodo para la deteccion de mutaciones de braf y pi3k.

Country Status (6)

Country Link
EP (2) EP2711432A1 (es)
CN (1) CN104685070B (es)
CA (1) CA2884869A1 (es)
ES (1) ES2712941T3 (es)
MX (1) MX362212B (es)
WO (1) WO2014044828A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE047958T2 (hu) * 2014-08-07 2020-05-28 Pharmassist Ltd A PIK3CA mutációs állapotának meghatározási módszere a mintában
CN109136367B (zh) * 2017-06-19 2022-03-18 格诺思博生物科技南通有限公司 提高braf基因v600e突变的诊断效率的方法
CN109234369A (zh) * 2018-10-21 2019-01-18 上海睿璟生物科技有限公司 一种检测人braf基因突变的pcr试剂盒

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB9902971D0 (en) * 1999-02-11 1999-03-31 Zeneca Ltd Assay
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
WO2010048691A1 (en) * 2008-10-28 2010-05-06 British Columbia Cancer Agency Branch Multiplex genotyping assay for detecting mutations in k-ras
JP2013501523A (ja) * 2009-08-11 2013-01-17 レスポンス ジェネティクス，インコーポレイティド Ｂｒａｆ変異の検出に有用な方法、プライマー、プローブ、及びキット
CN102234684B (zh) * 2010-04-23 2014-01-01 益善生物技术股份有限公司 Braf基因突变检测特异性引物和液相芯片
CN102234685B (zh) * 2010-04-23 2014-08-27 益善生物技术股份有限公司 一种pik3ca基因突变检测液相芯片

Also Published As

Publication number Publication date
CN104685070A (zh) 2015-06-03
EP2898093A1 (en) 2015-07-29
CA2884869A1 (en) 2014-03-27
CN104685070B (zh) 2019-01-11
MX2015003386A (es) 2015-06-05
EP2898093B1 (en) 2018-12-05
ES2712941T3 (es) 2019-05-16
EP2711432A1 (en) 2014-03-26
WO2014044828A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
GB201300533D0 (en) Methods of monitoring conditions by sequence analysis
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
WO2014028884A3 (en) Cancer diagnostics using biomarkers
TN2013000358A1 (en) Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
EP2576837A4 (en) CIRCULATING NUCLEIC ACID BIOMARKERS ASSOCIATED WITH PROSTATE CANCER
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX341866B (es) Metodo para usar expresion genica para determinar la probabilidad de un desenlace clinico de cancer renal.
MX2022012384A (es) Composiciones y metodos para cribar mutaciones en el cancer de tiroides.
WO2012031008A3 (en) Cancer-related biological materials in microvesicles
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
WO2015153732A8 (en) Use of double-stranded dna in exosomes: a novel biomarker in cancer detection
WO2014184679A3 (en) Method for the prognosis and treatment of renal cell carcinoma metastasis
WO2014028862A9 (en) Use of dna in circulating exosomes as a diagnostic marker for metastasic disease
GB201017978D0 (en) Multiplex amplification and detection
BR112012018545A2 (pt) método de determinação e confirmação da presença de um hpv em uma amostra
WO2016034715A3 (fr) Methode de prediction de l'evolution clinique du cancer colorectal
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
WO2013062261A3 (en) Newly identified colon cancer marker and diagnostic kit using the same
MX362212B (es) Metodo para la deteccion de mutaciones de braf y pi3k.
WO2012145516A3 (en) Methods and kits for quantitative determination of total organic acid content in a coolant
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
WO2013169771A3 (en) Methods and compositions for the prognosis and treatment of relapsed leukemia
WO2012101219A3 (en) Complex mirna sets as novel biomarkers for lung diseases
Chen et al. Comparison Of Plasma Circulating Free DNA Levels In Patients With Lung Cancer, Benign Lung Diseases And Healthy Controls
WO2014009055A9 (en) Method and kit for predicting or monitoring the response of a cancer patient to chemotherapy, based on measuring the expression level of tmem45a gene.

Legal Events

Date Code Title Description
FG Grant or registration